SPRB
HealthcareSpruce Biosciences, Inc.
$82.12
$-8.58 (-9.46%)
Jan 5, 2026
Price History (1Y)
Analysis
Spruce Biosciences, Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $87.90 million and 9 employees, the firm is a relatively small player in its industry. It has generated revenue of $697,000 over the trailing twelve months. The financials paint a picture of significant losses for Spruce Biosciences. Net income stands at -$47,879,000, with an EBITDA loss of -$49,462,000 and free cash flow of -$30,859,876. The company's gross margin is 0.0%, operating margin is -7100.0%, and profit margin is also 0.0%. Returns on equity and assets are -$167.9% and -$76.9%, respectively. The balance sheet shows a debt-to-equity ratio of 25.03, with $10.67 million in cash and $1.35 million in debt. The valuation metrics indicate that the company's stock is trading at an unfavorable price-to-book ratio of 8.59 and an even more negative forward P/E ratio of -2.49. The price-to-sales ratio is 126.11, while the EV/EBITDA ratio is -1.77.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $87.90M
- P/E Ratio
- N/A
- 52-Week High
- $2508.75
- 52-Week Low
- $7.00
- Avg Volume
- 184.00K
- Beta
- 3.63
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 9